Periprocedural management of rivaroxaban-treated patients

Bibliography

• Pottegård A, Poulsen BK, Larsen MD, et al. Dynamics of vitamin K antagonist and new oral anticoagulants use in atrial fibrillation: a Danish drug utilization study. J Thromb Haemost 2014;12:1413-18
   Google Scholar
• Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141:e326S-50S
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics; EMA. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human-med_001155.jsp&mid=WC0b01ac058001d124 [Last accessed 2014]
   Google Scholar
• Graff J, vonHentig N, Misselwitz F, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007;47:1398-407
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl):e278S-325S
   PubMedGoogle Scholar
• Imberti D, Dall’Asta C, Pierfranceschi MG. Oral factor xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med 2009;4(6):471-7
   PubMed Web of Science ®Google Scholar
• Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 2012;344:e3675
   PubMed Web of Science ®Google Scholar
• The EINSTEIN Investigators. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510
   PubMed Web of Science ®Google Scholar
• The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKETAF Investigators. Rivaroxaban vs. warfarin in non-valvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62
   PubMed Web of Science ®Google Scholar
• Plosker GL. Rivaroxaban: a review of its use in acute coronary syndromes. Drugs 2014;74(4):451-64
   Google Scholar
• Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematology Am Soc Hematol Educ Program 2012;2012:529-35
   Google Scholar
• Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(Suppl 2):e326S-50S
   PubMed Web of Science ®Google Scholar
• Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011;117(19):5044-9
   PubMed Web of Science ®Google Scholar
• Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004;110(16):2287-92
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e419S-94S
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective dresden NOAC registry. Eur Heart J 2014;35:1888-96
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51
   PubMed Web of Science ®Google Scholar
• Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin k antagonists systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012;126:1630-9
   PubMed Web of Science ®Google Scholar
• Omran H, Bauersachs R, Rübenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK online bRiDging REgistRy (BORDER). Thromb Haemost 2012;108:65-73
   PubMed Web of Science ®Google Scholar
• Santangeli P, Di Biase L, Pelargonio G, et al. Catheter ablation of atrial fibrillation: randomized controlled trials and registries, a look back and the view forward. J Interv Card Electrophysiol 2011;31:69-80
   Google Scholar
• Available from: https://www.medicines.org.uk/emc/medicine/21265/SPC/Xarelto+10+mg+film-coated+tablets/ [Last accessed 01 September 2014]
   Google Scholar
• Sie P, Samama CM, Godier A, et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. recommendations of the working group on perioperative haemostasis and the french study group on thrombosis and haemostasis. Arch Cardiovasc Dis 2011;104:669-76
   PubMed Web of Science ®Google Scholar
• Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:379-87
   PubMed Web of Science ®Google Scholar
• Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013;121(20):4032-5
   PubMed Web of Science ®Google Scholar
• Tripodi A, Chantarangkul V, Guinet C, et al. The INR calibrated for rivaroxaban-(INR rivaroxaban) has the potential to normalize PT results for rivaroxaban-treated patients. Results of an in-vitro study. J Thromb Haemost 2011;9:226-8
   PubMed Web of Science ®Google Scholar
• Tripodi A. Which test to measure the anticoagulant effect of rivaroxaban: the prothrombin time test. J Thromb Haemost 2013;11:576-8
   PubMed Web of Science ®Google Scholar
• Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem 2013;59:353-62
   PubMed Web of Science ®Google Scholar
• Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 2014;111(2):189-98
   PubMed Web of Science ®Google Scholar
• Lauw M, Coppens M, Eikelboom JW. Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. Can J Cardiol 2014;30:381-4
   Google Scholar
• Palareti G, Ageno W, Ferrari A, et al. Clinical management of rivaroxaban-treated patients. Expert Opin Pharmacother 2013;14:655-67
   PubMed Web of Science ®Google Scholar
• Imberti D, Benedetti R. Practical management of rivaroxaban for the treatment of venous thromboembolism. Clin Appl Thromb Hemost 2013. [Epub ahead of print]
   Google Scholar